Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Wacker Chemie AG
  6. News
  7. Summary
    WCH   DE000WCH8881

WACKER CHEMIE AG

(WCH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CAVACURMIN®: Study Reveals Increased Metabolic Bioavailability of Tetrahydrocurcumin

05/06/2021 | 05:15am EDT
CAVACURMIN®: Study Reveals Increased Metabolic Bioavailability of Tetrahydrocurcumin
Munich, May 06, 2021

A study recently published in the Journal of Functional Foods shows that ingestion of the curcumin-cyclodextrin complex CAVACURMIN® leads to an increased metabolic bioavailability of tetrahydrocurcumin. A large portion of supplemented curcumin is converted into tetrahydrocurcumin in the body. This metabolite is credited with anti-inflammatory and antioxidant properties. CAVACURMIN® is the only formulation on the market that demonstrably boosts the bioavailability of both curcumin and tetrahydrocurcumin.

CAVACURMIN® is a high-bioavailability complex of curcumin extract and gamma-cyclodextrin. Curcumin is extracted from turmeric. (photo: WACKER)

Curcumin, the active compound in turmeric, is a powerful antioxidant that supports healthy aging and joint health, as has been demonstrated in various studies. As it is not water-soluble, curcumin is not readily absorbed in the human bloodstream. Its bioavailability can be boosted significantly with the aid of gamma-cyclodextrin. A study published in 2018 shows that the curcuminoids of WACKER's cyclodextrin complex CAVACURMIN® are absorbed around 40 times more efficiently in the body than those of a standard curcumin extract (Purpura et al. 2018)1.

As part of a randomized double-blind study, it has now been shown that the metabolic bioavailability of tetrahydrocurcumin is also around 40 times higher following ingestion of CAVACURMIN® compared to a standard curcumin extract (Hundshammer et al. 2021)2.

Ingestion of the curcumin-cyclodextrin complex CAVACURMIN® leads to 40 times higher metabolic bioavailability of tetrahydrocurcumin (image: WACKER).

Tetrahydrocurcumin is a curcumin metabolite credited with additional health-promoting properties. The metabolic bioavailability gives the ratio of the in-vivo production of tetrahydrocurcumin to the absorbed amount of curcumin. Another finding of the long-term study is that, after only four weeks, daily ingestion of CAVACURMIN® (approx. 340 grams curcumin each time) leads to a consistently high blood concentration of curcumin and tetrahydrocurcumin. This effect can be measured after 12 weeks as well. The long-term study furthermore confirmed very high tolerability of CAVACURMIN®.

CAVACURMIN® can be easily processed in food supplements, such as tablets, capsules and energy bars or functional beverages.

About WACKER BIOSOLUTIONS

Using advanced biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-science sector - including pharmaceutical proteins, cyclodextrins and fermentation-generated cysteine. Its portfolio is also complemented by catalog chemicals, such as acetylacetone. The division focuses on developing customized solutions for growth sectors, such as food ingredients, pharmaceutical actives and agrochemicals.

Presspicture
CAVACURMIN® Kapseln

Inclusion in gammadextrin makes a hard-to-dissolve substance such as curcumin up to 40 times more absorbable by the human body, as shown in a recent clinical study. As a free-flowing powder, CAVACURMIN® is ideal for use in tablets, capsules, energy bars and beverages.

Order photo
Tetrahydrocurcurmin

Tetrahydrocurcurmin

Order photo
Contact

Wacker Chemie AG
Media Relations & Information
Manuela Dollinger

Tel. +49 89 6279-1629
Send message

close
close

Disclaimer

Wacker Chemie AG published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 09:14:01 UTC.


© Publicnow 2021
All news about WACKER CHEMIE AG
06/10WACKER CHEMIE AG  : Barclays keeps its Buy rating
MD
06/09WACKER CHEMIE AG  : Buy rating from Baader Bank
MD
06/08WACKER CHEMIE AG : Preliminary announcement of the publication of payment report..
EQ
06/02WACKER CHEMIE AG  : Kepler Cheuvreux reaffirms its Neutral rating
MD
06/02WACKER CHEMIE  : will Manufacture Upstream Products for Building-Protection Agen..
PU
06/01WACKER CHEMIE  : Unveils Highly Effective Silicone Emulsion for Hair Conditioner..
PU
05/26WACKER CHEMIE AG  : DZ Bank keeps its Buy rating
MD
05/19WACKER CHEMIE AG  : Barclays reiterates its Buy rating
MD
05/18WACKER CHEMIE AG  : NorldLB reaffirms its Neutral rating
MD
05/18WACKER CHEMIE AG  : UBS maintains a Buy rating
MD
More news
Financials
Sales 2021 5 363 M 6 503 M 6 503 M
Net income 2021 761 M 923 M 923 M
Net cash 2021 923 M 1 119 M 1 119 M
P/E ratio 2021 8,79x
Yield 2021 2,39%
Capitalization 7 007 M 8 498 M 8 496 M
EV / Sales 2021 1,13x
EV / Sales 2022 1,16x
Nbr of Employees 14 283
Free-Float 28,8%
Chart WACKER CHEMIE AG
Duration : Period :
Wacker Chemie AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WACKER CHEMIE AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 135,63 €
Last Close Price 141,05 €
Spread / Highest target 14,1%
Spread / Average Target -3,85%
Spread / Lowest Target -36,2%
EPS Revisions
Managers and Directors
NameTitle
Christian Hartel President & Chief Executive Officer
Peter-Alexander Wacker Chairman-Supervisory Board
Matthias Biebl Member-Supervisory Board
Franz-Josef Kortüm Member-Supervisory Board
Susanne Weiss Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
WACKER CHEMIE AG20.81%8 497
HEXPOL AB (PUBL)18.98%4 334
NOLATO AB (PUBL)6.97%2 877
TOKYO OHKA KOGYO CO., LTD.-1.93%2 683
SHANDONG HEAD CO.,LTD.147.29%2 670
ELKEM ASA7.54%2 345